Tributary Capital's Multi Cap Core strategy said in its Q2 letter that LivaNova's new product launches, services and cloud platform could lift sales in both segments; operating leverage and manufacturing efficiencies may turn growth into larger operating-profit gains.
The strategy said new cardiopulmonary products and related software, hardware and service revenue could accelerate sales. For Neuromodulation, it cited new products and expanded indications for vagus-nerve stimulation; it said the cloud-connected platform supports growth in both segments.
LivaNova closed at $77.16 on Sept. 23, 2026, down 4.50% over the prior month but up 46.19% over the prior year; its market capitalization was $4.23 billion. Hedge-fund portfolios holding the stock fell to 28 at the end of Q2 from 34 the previous quarter.
